Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

liz dallimore

  • Home
  •  
  • liz dallimore



  • Most Read
  • Latest Comments
  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    INOVIQ validates exosome therapy to target and kill breast cancer cells
    • News

  • EMVision analysis confirms hyperacute and acute ischaemia stroke detection capabilities
    EMVision analysis confirms hyperacute and acute ischaemia stroke detection capabilities
    • News

  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    • News

  • Argenica begins clinical trials of drug that could protect your brain during a stroke
    Argenica begins clinical trials of drug that could protect your brain during a stroke
    • News

  • Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    • News

  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    • News

    Argenica completes production of brain stroke drug, prepares for Phase 2 trial

    Biotech company Argenica Therapeutics Limited (ASX: AGN), which is developing novel therapeutics to reduce brain tissue death after stroke, has completed the production of its neuroprotective peptide candidate ARG-007 in powder form. The Company is gearing up for its Phase 2 clinical trials, and the final manufacturing of the sterile drug product in vials is

    Read More
    Public
  • Argenica begins clinical trials of drug that could protect your brain during a stroke
    • News

    Argenica begins clinical trials of drug that could protect your brain during a stroke

    Every 19 minutes, an Australian suffers a stroke, and every hour that the treatment is delayed, the brain ages up to four years. That paints a rather bleak picture, but that is exactly what biotech company Argenica Therapeutics Limited (ASX: AGN) is addressing as it receives ethics approval from Bellberry’s Human Research Ethics Committee (HREC)

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.